Fatal breakthrough infections in solid organ transplant recipients

In a cohort study of 664 722 patients who received at least 1 dose of a SARS-CoV-2 vaccine, solid organ transplant recipients had a higher rate for COVID-19 breakthrough infection and worse outcomes after full or partial vaccination, compared with persons without immune dysfunction. We describe 4 fatal breakthroughs with liver and kidney transplant recipients aged 13-69. 

Two vaccinated solid organ transplant recipients (68M, liver and 69M, renal transplant) infected with Alpha variant had severe pneumonia requiring intensive care admission and ventilatory support and subsequently died. Both got vaccinated with BNT162b2 mRNA (Pfizer-BioNTech), were on tacrolimus medication, spent over 40 days in ICU and received Dexamethasone and Tocilizumab as part of their COVID-19 treatment. Both had Diabetes mellitus and Hypertension.

These cases were a part of case series of four fully vaccinated solid organ transplant recipients who developed SARS-CoV-2 variants of concern breakthrough infections. Three patients received BNT162b2 mRNA (Pfizer-BioNTech) and one patient received ChAdOx1 (AZD12220) COVID-19 vaccines. The patients were infected with SARS-CoV-2 variants circulating in Saudi Arabia. Two patients were infected with Alpha variant and had severe pneumonia requiring intensive care admission and ventilatory support and subsequently died. The other two patients recovered; one patient was infected with Beta variant required low supplemental oxygen via nasal flow and the other patient was infected with Delta variant and required high supplemental oxygen nasal flow. Younger patients had a better outcome than older patients. 

READ MORE  

REFERENCE

Almaghrabi RS, Alhamlan FS, Dada A, Al-Tawfiq JA, Al Hroub MK, Saeedi MF, Alamri M, Alhothaly B, Alqasabi A, Al-Qahtani AA, Al-Omari A. Outcome of SARS-CoV-2 variant breakthrough infection in fully immunized solid organ transplant recipients. Journal of infection and public health. 2022 Jan 1;15(1):51-5.


A 13-year-old girl with a rare genetic disorder Kabuki syndrome, end stage renal disease and a liver transplant in 2017, developed high fever after a few weeks with COVID-19, was intubated and died two weeks later.  


REFERENCE

Girl With Rare Disease Dies From COVID Complications (yahoo.com)

'Take Covid Seriously,' Family Says Of Girl Who Died Of The Virus | Wauwatosa, WI Patch

Cedarburg mother honors legacy of daughter who died from COVID (jsonline.com)


A 55-year-old male, solid-organ-transplant recipient (kidney), vaccinated with Pfizer BNT162b2 vaccine, tested positive for  20I/S:501Y.V1/VOC-alpha variant of SARS-CoV-2. He developed cough, acute hypoxic respiratory failure, sepsis and died from COVID-19.  High viral load with Ct value of 22 was detected in the nasopharyngeal specimen.

READ MORE


REFERENCE

Deng X, Evdokimova M, O’Brien A, Rowe CL, Clark NM, Harrington A, Reid GE, Uprichard SL, Baker SC. Breakthrough infections with multiple lineages of SARS-CoV-2 variants reveals continued risk of severe disease in immunosuppressed patients. Viruses. 2021 Sep;13(9):1743.


Comments

Post a Comment

Popular posts from this blog

A New Onset of Ulcerative Colitis post-2nd-breakthrough-COVID-19

Image
A 21-year-old non-smoking Caucasian male with a history of acute pancreatitis but no other medical issues or family history had two doses of the BNT162b2 mRNA COVID-19 vaccine.  Four months after the second dose he had his first episode of COVID-19. Although not hypoxic, he felt pretty unwell for a week, with a severe cough, fever, generalized body ache, headache, and loss of taste. He received the third dose of the vaccine two months after recovering from COVID. Nine months after the third dose, he had the second episode of COVID-19, during which he was mildly unwell for three days, recovered, and did not require any anti-viral medication or antibiotics. One week post the second episode of COVID-19, he developed diarrhea and abdominal pain. It then progressed to bloody diarrhea. Ulcerative colitis was diagnosed based on his clinical symptoms, biopsy changes, and the exclusion of other causes.  There are ten published case reports about the newly diagnosed ulcerative colitis associate
Read more

COVID in May

Image
Concerns about a potential resurgence of COVID-19 are mounting as summer 2024 approaches.  This is driven by several indicators, including social media posts, healthcare data, and wastewater surveillance across different regions. Our study findings corroborate this trend.  While many forecasters anticipate a surge, others expect a gradual increase through the end of May, and then a decline again around early June. Reports from social media suggest emerging clusters of COVID-19 in Texas, several Canadian provinces, the UK, and on cruises in northern regions such as a Norwegian cruise to Alaska.  Data from Alberta's Respiratory virus dashboard   (total weekly laboratory-confirmed COVID-19 cases) and wastewater surveillance in Calgary indicate an uptick in COVID-19 cases starting April 2024. The most recent statistics from Alberta Health reveal a significant increase in hospitalizations due to COVID-19, with 114 individuals currently hospitalized—an increase of more than 20% over two
Read more

Chronic SARS-CoV-2 Shedding

Image
Chronic viral shedding, a condition where the virus continues to be released from an individual's body long after the initial infection, has been observed in many infectious diseases, including COVID-19.  In such cases, individuals may remain asymptomatic or experience only mild symptoms while the virus persists. It remains detectable in repeated tests over an extended period and can still infect others even in nasal swab is negative (which happens quite often ). This was evident in our study.    Recent research by Conway et al. (2024) highlights the possibility of chronic SARS-CoV-2 infection, extending over several months and potentially years. Other studies have documented prolonged asymptomatic infections and extended viral shedding in moderate to severe beyond hospital discharge. Analysis of sequencing data on UK samples taken between 2 November 2020 and 15 August 2022 lead to estimates that 0.1–0.5% of infections may become persistent with typically rebounding high viral load
Read more